Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial

被引:108
作者
Blair, John E. A. [2 ]
Pang, Peter S. [1 ]
Schrier, Robert W. [3 ]
Metra, Marco [4 ]
Traver, Brian [5 ]
Cook, Thomas
Campia, Umberto [1 ]
Ambrosy, Andrew [1 ]
Burnett, John C., Jr. [6 ]
Grinfeld, Liliana [7 ]
Maggioni, Aldo P. [8 ]
Swedberg, Karl [9 ]
Udelson, James E. [10 ]
Zannad, Faiez [11 ]
Konstam, Marvin A. [10 ]
Gheorghiade, Mihai [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA
[2] Wilford Hall USAF Med Ctr, San Antonio, TX 78236 USA
[3] Univ Colorado, Denver, CO 80202 USA
[4] Univ Brescia, Brescia, Italy
[5] Univ Wisconsin, Madison, WI USA
[6] Mayo Clin, Rochester, MN USA
[7] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[8] ANMCO Res Ctr, Florence, Italy
[9] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden
[10] Tufts Med Ctr, Boston, MA USA
[11] CHU, INSERM, U961, CIC9501, Nancy, France
关键词
Hospitalization; Heart failure; Acute heart failure syndromes; Renal function; FOLLOW-UP; OUTCOMES; TOLVAPTAN; SURVIVAL; IMPACT; PREDICTORS; ANTAGONIST; CREATININE; INCREASES; ADMISSION;
D O I
10.1093/eurheartj/ehr238
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To provide an in-depth clinical characterization and analysis of outcomes of the patients hospitalized for heart failure (HF) who subsequently develop worsening renal function (WRF) during hospitalization or soon after discharge. Of the 4133 patients hospitalized with worsening HF and reduced left ventricular ejection fraction (LVEF) (40) in the EVEREST trial, 2072 were randomized to tolvaptan, a selective vasopressin-2 receptor antagonist, and 2061 were randomized to placebo, both in addition to standard therapy. This analysis included the 2021 (98) patients in the placebo group with a complete set of renal function parameters. Renal function parameters and clinical variables were measured prospectively during hospitalization and after discharge. Worsening renal function was defined as an increase in sCr epsilon 0.3 mg/dL during the in-hospital (randomization to discharge or Day 7) and post-discharge (discharge or Day 7 to 4 weeks post-discharge) periods. Blood pressure (BP), body weight (BW), natriuretic peptides (NPs), and congestion score were correlated with WRF. The prognostic value of baseline renal function at admission and WRF during hospitalization and post-discharge on long-term outcomes were assessed using a Cox proportional hazards model adjusted for other baseline covariates. At randomization, 53.2 of patients had moderately or severely reduced estimated glomerular filtration rate (eGFR) (60.0 mL/min/1.73 m(2)). Worsening renal function was observed in 13.8 in-hospital and 11.9 post-discharge. Worsening renal function during hospitalization and post-discharge was associated with greater reductions in BP, BW, and NPs. Baseline renal dysfunction as well as in-hospital and post-discharge WRF were predictive of a composite endpoint of cardiovascular (CV) mortality/HF rehospitalization. The prevalence of renal dysfunction is high in patients hospitalized for HF with reduced LVEF. Worsening renal function may occur not only during hospitalization, but also in the early post-discharge period. Since worsening renal function during hospitalization is associated with a significant decrease in signs and symptoms of congestion, body weight and natriuretic peptides, which are good prognostic indicators, worsening renal function during hospitalization as an endpoint in clinical trials should be re-evaluated.
引用
收藏
页码:2563 / 2572
页数:10
相关论文
共 34 条
  • [1] Neutrophil Gelatinase-Associated Lipocalin in the Diagnosis of Type 1 Cardio-Renal Syndrome in the General Ward
    Alvelos, Margarida
    Pimentel, Rodrigo
    Pinho, Elika
    Gomes, Andre
    Lourenco, Patricia
    Teles, Maria Jose
    Almeida, Pedro
    Guimaraes, Joao Tiago
    Bettencourt, Paulo
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (03): : 476 - 481
  • [2] Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial†
    Blair, John E. A.
    Khan, Sadiya
    Konstam, Marvin A.
    Swedberg, Karl
    Zannad, Faiez
    Burnett, John C., Jr.
    Grinfeld, Liliana
    Maggioni, Aldo P.
    Udelson, James E.
    Zimmer, Christopher A.
    Ouyang, John
    Chen, Chien-Feng
    Gheorghiade, Mihai
    [J]. EUROPEAN HEART JOURNAL, 2009, 30 (13) : 1666 - 1673
  • [3] Relationship between heart failure treatment and development of worsening renal function among hospitalized patients
    Butler, J
    Forman, DE
    Abraham, WT
    Gottlieb, SS
    Loh, E
    Massie, BM
    O'Connor, CM
    Rich, MW
    Stevenson, LW
    Wang, YF
    Young, JB
    Krumholz, HM
    [J]. AMERICAN HEART JOURNAL, 2004, 147 (02) : 331 - 338
  • [4] Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate
    Damman, Kevin
    Van Veldhuisen, Dirk J.
    Navis, Gerjan
    Vaidya, Vishal S.
    Smilde, Tom D. J.
    Westenbrink, B. Daan
    Bonventre, Joseph V.
    Voors, Adriaan A.
    Hillege, Hans L.
    [J]. HEART, 2010, 96 (16) : 1297 - 1302
  • [5] Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH)
    Damman, Kevin
    Jaarsma, Tiny
    Voors, Adriaan A.
    Navis, Gerjan
    Hillege, Hans L.
    van Veldhuisen, Dirk J.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (09) : 847 - 854
  • [6] K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword
    Eknoyan, G
    Levin, NW
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) : S14 - S266
  • [7] Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes Lessons Learned and Directions Forward
    Felker, G. Michael
    Pang, Peter S.
    Adams, Kirkwood F.
    Cleland, John G. F.
    Cotter, Gad
    Dickstein, Kenneth
    Filippatos, Gerasimos S.
    Fonarow, Gregg C.
    Greenberg, Barry H.
    Hernandez, Adrian F.
    Khan, Sadiya
    Komajda, Michel
    Konstam, Marvin A.
    Liu, Peter P.
    Maggioni, Aldo P.
    Massie, Barry M.
    McMurray, John J.
    Mehra, Mandeep
    Metra, Marco
    O'Connell, John
    O'Connor, Christopher M.
    Pina, Ileana L.
    Ponikowski, Piotr
    Sabbah, Hani N.
    Teerlink, John R.
    Udelson, James E.
    Yancy, Clyde W.
    Zannad, Faiez
    Gheorghiade, Mihai
    [J]. CIRCULATION-HEART FAILURE, 2010, 3 (02) : 314 - 325
  • [8] Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure
    Forman, DE
    Butler, J
    Wang, YF
    Abraham, WT
    O'Connor, CM
    Gottlieb, SS
    Loh, E
    Massie, BM
    Rich, MW
    Stevenson, LW
    Young, JB
    Krumholz, HM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (01) : 61 - 67
  • [9] Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome Study with Tolvaptan (EVEREST)
    Gheorghiade, M
    Orlandi, C
    Burnett, JC
    Demets, D
    Grinfeld, L
    Maggioni, A
    Swedberg, K
    Udelson, JE
    Zannad, F
    Zimmer, C
    Konstam, MA
    [J]. JOURNAL OF CARDIAC FAILURE, 2005, 11 (04) : 260 - 269
  • [10] Acute heart failure syndromes -: Current state and framework for future research
    Gheorghiade, M
    Zannad, F
    Sopko, G
    Klein, L
    Piña, IL
    Konstam, MA
    Massie, BM
    Roland, E
    Targum, S
    Collins, SP
    Filippatos, G
    Tavazzi, L
    [J]. CIRCULATION, 2005, 112 (25) : 3958 - 3968